Wall Street analysts expect Johnson & Johnson (NYSE:JNJ) to announce $2.31 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Johnson & Johnson’s earnings, with the lowest EPS estimate coming in at $2.22 and the highest estimate coming in at $2.38. Johnson & Johnson posted earnings per share of $2.30 during the same quarter last year, which indicates a positive year over year growth rate of 0.4%. The firm is expected to issue its next earnings results before the market opens on Tuesday, April 20th.
On average, analysts expect that Johnson & Johnson will report full year earnings of $9.48 per share for the current year, with EPS estimates ranging from $9.40 to $9.55. For the next financial year, analysts anticipate that the company will post earnings of $10.22 per share, with EPS estimates ranging from $10.09 to $10.47. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.82 by $0.04. The firm had revenue of $22.50 million during the quarter, compared to analysts’ expectations of $21.62 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.88 earnings per share.
A number of research analysts recently issued reports on JNJ shares. Morgan Stanley boosted their target price on Johnson & Johnson from $178.00 to $187.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 27th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Wednesday, January 27th. SVB Leerink upped their target price on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 26th. Finally, Raymond James increased their price objective on shares of Johnson & Johnson from $158.00 to $183.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $178.60.
Shares of Johnson & Johnson stock traded up $0.25 during trading hours on Thursday, reaching $163.86. 26,472 shares of the company were exchanged, compared to its average volume of 8,177,090. The firm has a market cap of $431.40 billion, a PE ratio of 25.76, a PEG ratio of 3.06 and a beta of 0.70. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. Johnson & Johnson has a 1 year low of $133.65 and a 1 year high of $173.65. The stock’s fifty day moving average is $161.06 and its 200 day moving average is $154.38.
A number of institutional investors and hedge funds have recently made changes to their positions in JNJ. Norges Bank acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,370,566,000. Sanders Capital LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $1,126,076,000. Morgan Stanley grew its position in shares of Johnson & Johnson by 7.3% during the fourth quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock worth $3,794,594,000 after acquiring an additional 1,638,263 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 31,958,260 shares of the company’s stock valued at $5,029,590,000 after acquiring an additional 1,628,229 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Johnson & Johnson by 574.1% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,557,719 shares of the company’s stock worth $245,154,000 after purchasing an additional 1,326,651 shares during the period. 67.25% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.